ClinicalTrials.gg
Active, not recruitingNCT02393625Updated Sep 17, 2026

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

A Phase 1 interventional study of Ceritinib (LDK378) and Nivolumab in ALK-positive NSCLC, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 12 sites in 8 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing ceritinib in Carcinoma, Non-Small-Cell Lung — none open to participants now, 2 under way, none of them phase 3. ceritinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
9th of 16
57 · median 80
Started
2015
with 4 others
Phase 1
6 of 16
none open now
Registered
11th of 16
by date
Lead sponsor
11 of 16
Novartis Pharmaceuticals

Among the 16 studies testing ceritinib in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by enrollment, is one of 5 that started in 2015, is one of 6 in phase 1, and was the 11th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

None of the 16 studies testing ceritinib in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →

About ceritinib

ceritinib: first FDA approval 2014 (ZYKADIA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing ceritinib in Carcinoma, Non-Small-Cell Lung as a file.
02

Study summary

This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients

03

Conditions studied

  • ALK-positive NSCLC

Keywords

  • NSCLC, ALK-positive
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of NSCLC that carries an ALK rearrangement
  • Stage IIIB or IV NSCLC or locally advanced or NSCLC
  • Presence of at least one as defined by 1.1
  • Patients who have received prior chemotherapy, other ALK inhibitors, biologic therapy, or other agents, must have recovered from all toxicities related to prior anticancer therapies to grade ≤1 ( v 4.03). Patients with grade ≤ 2 peripheral neuropathy or any grade of alopecia, fatigue, nail changes or skin changes are allowed to enter the study
  • Patient has a 0-1

Exclusion criteria

Exclusion Criteria:

  • Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years
  • Patients with an active, known or suspected disease
  • Unable or unwilling to swallow tablets or capsules
  • Patient has other severe, acute, or chronic medical conditions including uncontrolled diabetes mellitus or psychiatric conditions or laboratory abnormalities that in the opinion of the Investigator may increase the risk associated with study participation, or that may interfere with the interpretation of study results
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Dose Escalation

    Drug: Ceritinib (LDK378) · Drug: Nivolumab

  • Experimental
    Dose Expansion

    Drug: Ceritinib (LDK378) · Drug: Nivolumab

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) and/or Recommended Dose for Expansion

    Time frame: Study Day 42 (6 weeks)

  2. Overall response rate (ORR)

    ORR (complete response (CR)+ partial response (PR)) per RECIST 1.1 as assessed by investigator

    Time frame: 24 Weeks

Secondary outcomes

  1. Duration of Response (DOR)

    Time frame: 24 weeks

  2. Disease Control Rate (DCR)

    Time frame: 24 weeks

  3. Time to Response (TTR)

    Time frame: 24 weeks

  4. Progression Free Survival (PFS)

    Time frame: 24 weeks

  5. Overall survival (OS)

    Time frame: 24 weeks

07

Study locations

12 sites
  • Mayo Clinic - Arizona
    Scottsdale, Arizona 85259, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Massachusetts General Hospital Thoracic Oncolgoy
    Boston, Massachusetts 02115, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Novartis Investigative Site
    Heidelberg, Victoria 3084, Australia
  • Novartis Investigative Site
    Leuven, Vlaams Brabant 3000, Belgium
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Hong Kong, 999077, Hong Kong
  • Novartis Investigative Site
    Milan, MI 20133, Italy
  • Novartis Investigative Site
    Modena, MO 41124, Italy
  • Novartis Investigative Site
    Singapore, 168583, Singapore
  • Novartis Investigative Site
    Barcelona, 08035, Spain
08

References and documents

Publications

  • Spigel DR, Reynolds C, Waterhouse D, Garon EB, Chandler J, Babu S, Thurmes P, Spira A, Jotte R, Zhu J, Lin WH, Blumenschein G Jr. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). J Thorac Oncol. 2018 May;13(5):682-688. doi: 10.1016/j.jtho.2018.02.022. Epub 2018 Mar 6. PubMed 29518553 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2015 (actual). Primary completion is estimated for Apr 2027, 142 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 142 months is above that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2015
First posted
Mar 19, 2015
StartActual
May 27, 2015
Primary completionEst.
Apr 9, 2027
CompletionEst.
Apr 9, 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02393625
Responsible party
Sponsor
First posted
Mar 19, 2015
Start date
May 27, 2015
Primary completion
Apr 9, 2027 (estimated)
Completion
Apr 9, 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ceritinib · Nivolumab

Start the discussion